Expected Trial Completion for PRGN-2012
Jun 5, 2026, 4:00:00 AM — trial completion
Summary
Precigen's Phase 1/2 clinical trial of PRGN-2012 in adult patients with recurrent respiratory papillomatosis is projected to complete on June 5, 2026. The study evaluates the safety and efficacy of PRGN-2012, an investigational therapeutic candidate, across two dose levels. PRGN-2012 is a novel immunotherapy designed for the treatment of recurrent respiratory papillomatosis, a rare disease caused by HPV infection. The trial is no longer recruiting and enrolled 38 participants.
Company
PRECIGEN INC (PGEN)NASDAQ — Healthcare: Services, Biotechnology: Services-Commercial Physical & Biological Research
www.precigen.comSimilar Events
Expected Trial Completion of PRGN-2012 in RRP
Precigen's confirmatory Phase 3 trial of PRGN-2012, a therapeutic candidate for recurrent respiratory papillomatosis (RRP), is expected to complete on March 1, 2029. The single-arm, open-label study is evaluating efficacy and safety in patients with a history of repeated surgical debulking. PRGN-2012 is an investigational immunotherapy designed to address RRP, a rare disease caused by HPV infection.
trial completionPRGN-2009 Phase 2 Trial Completion in Cervical Cancer
Precigen is conducting a Phase 2 randomized trial (NCT06157151) evaluating PRGN-2009, an investigational immunotherapy, in combination with pembrolizumab versus pembrolizumab alone in patients with recurrent or metastatic cervical cancer resistant to pembrolizumab. The trial, which began in November 2024, is expected to complete on January 30, 2028. PRGN-2009 is a therapeutic vaccine targeting HPV-associated cancers. The study aims to assess efficacy and safety in a population with limited treatment options.
trial completionPhase I/Ib Trial Completion for PRGN-3005 in Advanced Ovarian Cancer
Precigen is expected to complete its Phase I/Ib clinical trial of PRGN-3005, an autologous CAR T cell therapy, for patients with advanced, recurrent, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer on 15 November 2028. The study aims to evaluate safety and determine the recommended dose of PRGN-3005, a genetically engineered cell therapy designed to target tumor cells. The trial is currently active but not recruiting, with an enrollment of 71 participants.
trial completionExpected Trial Completion for PRGN-3007 UltraCAR-T Cells
The Phase 1 clinical trial evaluating PRGN-3007 UltraCAR-T cells in patients with advanced ROR1-positive hematologic malignancies, including CLL, MCL, ALL, DLBCL, and solid tumor TNBC, is expected to complete by March 1, 2026. The study, sponsored by H. Lee Moffitt Cancer Center and Research Institute, investigates the safety and preliminary efficacy of this investigational CAR-T cell therapy developed by Precigen (PGEN).
trial completion